TGFB1 and neoplasm: Strategies to “armor” CAR-T cells against the hostile tumor microenvironment include the incorporation of pro-inflammatory cytokines (IL-12), co-stimulatory ligands (4-1BBL; CD40L), or dominant negative receptors (TGF-β) into the CAR construct [69, 70].